SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
+3.37%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$277M
AUM Growth
+$277M
(-4.1%)
Cap. Flow
-$58.1M
Cap. Flow
% of AUM
-20.99%
Top 10 Holdings %
Top 10 Hldgs %
46.92%
Holding
254
New
38
Increased
26
Reduced
76
Closed
42
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$8.46M |
| 2 |
CELG
Celgene Corp
CELG
|
$3.94M |
| 3 |
United Therapeutics
UTHR
|
$3.32M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
$2.76M |
| 5 |
Tenet Healthcare
THC
|
$2.56M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$15.2M |
| 2 |
VXZ
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
|
$6.65M |
| 3 |
Abbott
ABT
|
$6.42M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$4.21M |
| 5 |
SCON
Superconductor Technologies Inc.
SCON
|
$3.87M |
Sector Composition
| 1 | Healthcare | 87.44% |
| 2 | Consumer Staples | 0.39% |
| 3 | Technology | 0.24% |
| 4 | Industrials | 0.1% |
| 5 | Materials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sarepta Therapeutics
SRPT
$1.78B
| $32.9M | 1.23% | 536,282 -247,215 | -32% | -$15.2M |
|
2
Regeneron Pharmaceuticals
REGN
$61.5B
| $30.5M | 1.14% | 75,919 +4,394 | +6% | +$1.77M |
|
3
Amgen
AMGN
$155B
| $22.2M | 0.83% | 133,176 -20,906 | -14% | -$3.49M |
|
4
Outlook Therapeutics
OTLK
$37.8M
| $9.64M | 0.36% | 2,268,585 +199,617 | +10% | +$849K |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $8.46M | 0.32% | +156,887 | New | +$8.46M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $6.04M | 0.23% | 31,172 +1,622 | +5% | +$314K |
|
7
Tenax Therapeutics
TENX
$27.3M
| $5.55M | 0.21% | 2,412,857 -193,178 | -7% | -$444K |
|
8
Dynavax Technologies
DVAX
$1.19B
| $5.47M | 0.21% | 521,875 +231,370 | +80% | +$2.43M |
|
|
9
Abbott
ABT
$231B
| $4.77M | 0.18% | 112,888 -151,812 | -57% | -$6.42M |
|
|
CELG
10
DELISTED
Celgene Corp
CELG
| $3.94M | 0.15% | +37,728 | New | +$3.94M |
|
11
Regenxbio
RGNX
$451M
| $3.69M | 0.14% | 263,177 -148,749 | -36% | -$2.08M |
|
12
Plus Therapeutics
PSTV
$45.3M
| $3.58M | 0.13% | 1,762,846 -203,862 | -10% | -$414K |
|
|
OPGN
13
DELISTED
OpGen, Inc
OPGN
| $3.55M | 0.13% | 2,161,467 +536,467 | +33% | +$880K |
|
|
14
United Therapeutics
UTHR
$13.8B
| $3.32M | 0.12% | +28,112 | New | +$3.32M |
|
|
EIGR
15
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.09M | 0.12% | 230,803 +55,554 | +32% | +$744K |
|
16
Arbutus Biopharma
ABUS
$711M
| $3.02M | 0.11% | 878,531 -297,500 | -25% | -$1.02M |
|
17
Indaptus Therapeutics
INDP
$7.19M
| $2.9M | 0.11% | 498,006 -245,539 | -33% | -$1.43M |
|
|
LJPC
18
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $2.88M | 0.11% | 120,964 -85,167 | -41% | -$2.03M |
|
|
PVLA
19
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $2.82M | 0.11% | 1,543,307 -72,685 | -4% | -$133K |
|
|
TSRO
20
DELISTED
TESARO, Inc.
TSRO
| $2.76M | 0.1% | +27,500 | New | +$2.76M |
|
|
21
Tenet Healthcare
THC
$16.3B
| $2.56M | 0.1% | +112,831 | New | +$2.56M |
|
22
DURECT Corp
DRRX
$59.6M
| $2.5M | 0.09% | 1,800,000 -740,278 | -29% | -$1.03M |
|
|
SPHS
23
DELISTED
Sophiris Bio, Inc.
SPHS
| $2.35M | 0.09% | +757,033 | New | +$2.35M |
|
|
PRTK
24
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $2.28M | 0.09% | 175,000 -130,964 | -43% | -$1.7M |
|
|
VXZ
25
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
| $2.22M | 0.08% | 65,000 -195,000 | -75% | -$6.65M |
|